Yes, if the news is positive and PD becomes a CDx to Invokana then what's a few months more wait?
The most important thing about that report is Jannsen sought out PIQ for their Phase3 and specifically why. As mentioned in the report, they  desperately need a way to reverse the depreciation of sales on Invokana due to the boxed warnings that got placed. Leveraging PromarkerD to identify high-risk patients and beginning treatment earlier can extend the life of the patients kidneys which improves Jannsens clinical outcome. Then in addition the bigger positive is that Jannsen would capture a patient group years earlier than they would normally and more importantly before their competitors!!
Sounds like a win - win to both companies, just a matter of licence and royalty negotiations.
Market is currently a dog's breakfast so won't be surprised to see a non-reaction on positive news, unfortunately that's just how the cookie has crumbled for our dear Proteomics international.
I'm still optimistic long-term for potential biomarker discovery for endometriosis and growing analytical services revenue.
Cheers and good luck all, stay safe.
PIQ Price at posting:
26.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)